ArticleJournal of laboratory physicians
Prevalence and characterization of beta-lactamase-producing
Article in Journal of laboratory physicians. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Article
- Partial purification and environmental application of CTX-type ESBL beta-lactamases from wastewater-derived E. coli isolates.BMC microbiology · 2026Article
- Article
- Article
- Exploring New Delhi Metallo Beta Lactamases in Klebsiella pneumoniae and Escherichia coli: genotypic vs. phenotypic insights.Annals of clinical microbiology and antimicrobials · 2025Article
- Risk of Colonization with Multidrug-Resistant Gram-Negative Bacteria Among Travellers and Migrants: A Narrative Review.Tropical medicine and infectious disease · 2025Review
- Emerging Trends of Beta-Lactamases in Western Nepal: A Growing Public Health Concern.International journal of microbiology · 2025Article
- Article
- Review
- Article
- Molecular Characterization of Extended Spectrum β-Lactamase ProducingJournal of laboratory physicians · 2023Article
- Transient comparison of techniques to counter multi-drug resistant bacteria: prime modules in curation of bacterial infections.Frontiers in antibiotics · 2023Review
- Virulence-associated genes analysis of carbapenemase-producing Escherichia coli isolates.PloS one · 2022Article
- High prevalence of multiple antibiotic resistance in clinical E. coli isolates from Bangladesh and prediction of molecular resistance determinants using WGS of an XDR isolate.Scientific reports · 2021Article
- Article
- Prevalence, serotyping and drug susceptibility patterns ofWorld journal of biological chemistry · 2020Article
- Increasing Prevalence ofInternational journal of applied & basic medical researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe purpose of the study was to determine the prevalence and characterize the resistance profiles of MATERIALS AND
methodsA total of 196 consecutive, nonduplicate strains of clinically significant
resultsOverall prevalence of ESBLs, Amp C, and carbapenemase production was found to be 88.3%, 42.2%, and 65.1% by the phenotypic detection methods. Our study also revealed high resistance rates against other antibiotics such as cefepime (89%), cefotaxime (95.4%), ceftazidime (85.4%), ceftriaxone (91.8%), cefpodoxime (92.7%), aztreonam (56.3%), piperacillin/tazobactam (89.2%), and ticarcillin/clavulanic acid (76.3%). The most prevalent ESBL gene was bla
conclusionOur findings suggest a high rate of ESBLs, Amp C, and carbapenemase production among the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.